InMed Pharmaceuticals Inc. (INM)
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $1.33
- As of
Kresmion compiles this page from INM's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
InMed Pharmaceuticals Inc. (INM): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-18.
See the full INM dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for INM on one page. Preview it with sample data, then open it live with a free account.
Preview the INM dossierActive signals for INM
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in INM
- mediumEARNINGS_MISS
Q4-2022: Missed consensus by 152.6% - EPS $-280.6 vs $-111.1 estimate
- mediumEARNINGS_MISS
Missed consensus by 152.6% - EPS $-280.6 vs $-111.1 estimate
FREE, NO ACCOUNT
Every signal on INM, as it fires
New filings, 13F moves and cross asset signals on INM land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in INM (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 457637700 · 2026Q2 | $40K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, INM
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
INM against its peers
INM's return on equity of -1168.4% ranks in the 6th percentile of 7 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | INM | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 4.5M | n/a | 9 |
| Gross margin | n/a | 53.7% | n/a | 7 |
| Operating margin | n/a | -17.8% | n/a | 8 |
| Net margin | n/a | -23.1% | n/a | 8 |
| Return on equity | -1168.4% | -65.3% | 6 | 7 |
| 1 year | -37.6% | -32.0% | 50 | 8 |
Peers (11): APUS, SNOA, CABR, BIOE, BFRI, BUDZ, HYEX, IMCC, PRFX, CVSI, AYTU. Left out: GELS (period gap), PLSH (period gap), AKAN (period gap), YCBD (period gap), TRUFF (no annual filing), RDHL (period gap), CNTMF (no annual filing), LVRLF (period gap), CTTH (period gap), OPTH (no annual filing), UPC (period gap), ROMJF (no annual filing), CBIH (period gap), MCUJF (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (INM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow INM on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to INM for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.